Press Releases

CRANBURY, N.J. and BUDAPEST, Hungary, Sept. 3, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN; hereinafter: “Palatin”) and Gedeon Richter Plc. (hereinafter: “Richter”) announced that they have entered into a collaboration and license agreement to co-develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications in the European Union, other European countries and additional […]

CRANBURY, N.J., July 9, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application

CRANBURY, N.J., June 27, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it is joining the Russell Microcap® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes

CRANBURY, N.J., June 10, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application

RED BANK, N.J., May 20, 2014 /PRNewswire/ — Nearly one in two non-menopausal women ages 30 to 50 say they have experienced low sexual desire at some point in their lives, and many of these women (61%) felt distressed by it, according to a new national survey. Low sexual desire that is accompanied by distress

CRANBURY, N.J., May 13, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2014.  Recent Highlights Pivotal Phase 3 clinical trials of bremelanotide for Female

CRANBURY, N.J., May 9, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2014 operating results on Tuesday, May 13, 2014 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 13,

CRANBURY, N.J., April 29, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunction were presented at the American College of Obstetricians and Gynecologists (ACOG) 2014 Annual Clinical Meeting in Chicago, IL on Monday, April 28,

CRANBURY, N.J., March 31, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has granted an extension until April 30, 2014 to an existing option agreement with a potential commercial partner for

CRANBURY, N.J., March 6, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 26th Annual ROTH Conference on Tuesday, March 11, 2014, at 3:30 p.m. Pacific Time.  The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA. Carl Spana, Ph.D., President and